Premium
Allurion Technologies Inc (ALUR)
NYSE
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient ... Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts. Show more
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock...
AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024...
19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on...
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S...
In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle...
Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health Allurion Technologies, Inc. (NYSE: ALUR), a...
Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York...
In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0392 | -11.1680911681 | 0.351 | 0.3799 | 0.301 | 410546 | 0.34698277 | CS |
| 4 | -0.0781 | -20.0307771223 | 0.3899 | 0.5699 | 0.301 | 855688 | 0.38350623 | CS |
| 12 | -0.2982 | -48.8852459016 | 0.61 | 0.8 | 0.301 | 402405 | 0.44822888 | CS |
| 26 | -1.1182 | -78.1958041958 | 1.43 | 3.55 | 0.301 | 876144 | 1.82951215 | CS |
| 52 | -3.1682 | -91.0402298851 | 3.48 | 4 | 0.301 | 710075 | 2.26654015 | CS |
| 156 | -8.6882 | -96.5355555556 | 9 | 9 | 0.301 | 540511 | 2.39493184 | CS |
| 260 | -8.6882 | -96.5355555556 | 9 | 9 | 0.301 | 540511 | 2.39493184 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
